IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses.

Breast Cancer · 2025 · PMC11993443 · PMID 40128415

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

IRSN-23 exhibited a highly significant correlation coefficient (Pearson correlation coefficient r = 0.98) in microarray and RNA-Seq analyses of the corresponding samples.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.